332 related articles for article (PubMed ID: 7809080)
1. RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex.
Chiu MI; Katz H; Berlin V
Proc Natl Acad Sci U S A; 1994 Dec; 91(26):12574-8. PubMed ID: 7809080
[TBL] [Abstract][Full Text] [Related]
2. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells.
Sabers CJ; Martin MM; Brunn GJ; Williams JM; Dumont FJ; Wiederrecht G; Abraham RT
J Biol Chem; 1995 Jan; 270(2):815-22. PubMed ID: 7822316
[TBL] [Abstract][Full Text] [Related]
3. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs.
Sabatini DM; Erdjument-Bromage H; Lui M; Tempst P; Snyder SH
Cell; 1994 Jul; 78(1):35-43. PubMed ID: 7518356
[TBL] [Abstract][Full Text] [Related]
4. Interaction between FKBP12-rapamycin and TOR involves a conserved serine residue.
Stan R; McLaughlin MM; Cafferkey R; Johnson RK; Rosenberg M; Livi GP
J Biol Chem; 1994 Dec; 269(51):32027-30. PubMed ID: 7528205
[TBL] [Abstract][Full Text] [Related]
5. TOR mutations confer rapamycin resistance by preventing interaction with FKBP12-rapamycin.
Lorenz MC; Heitman J
J Biol Chem; 1995 Nov; 270(46):27531-7. PubMed ID: 7499212
[TBL] [Abstract][Full Text] [Related]
6. Missense mutations at the FKBP12-rapamycin-binding site of TOR1.
Freeman K; Livi GP
Gene; 1996 Jun; 172(1):143-7. PubMed ID: 8654975
[TBL] [Abstract][Full Text] [Related]
7. The rapamycin and FKBP12 target (RAFT) displays phosphatidylinositol 4-kinase activity.
Sabatini DM; Pierchala BA; Barrow RK; Schell MJ; Snyder SH
J Biol Chem; 1995 Sep; 270(36):20875-8. PubMed ID: 7673106
[TBL] [Abstract][Full Text] [Related]
8. A mammalian protein targeted by G1-arresting rapamycin-receptor complex.
Brown EJ; Albers MW; Shin TB; Ichikawa K; Keith CT; Lane WS; Schreiber SL
Nature; 1994 Jun; 369(6483):756-8. PubMed ID: 8008069
[TBL] [Abstract][Full Text] [Related]
9. Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue.
Chen J; Zheng XF; Brown EJ; Schreiber SL
Proc Natl Acad Sci U S A; 1995 May; 92(11):4947-51. PubMed ID: 7539137
[TBL] [Abstract][Full Text] [Related]
10. FKBP12-rapamycin target TOR2 is a vacuolar protein with an associated phosphatidylinositol-4 kinase activity.
Cardenas ME; Heitman J
EMBO J; 1995 Dec; 14(23):5892-907. PubMed ID: 8846782
[TBL] [Abstract][Full Text] [Related]
11. Dominant missense mutations in a novel yeast protein related to mammalian phosphatidylinositol 3-kinase and VPS34 abrogate rapamycin cytotoxicity.
Cafferkey R; Young PR; McLaughlin MM; Bergsma DJ; Koltin Y; Sathe GM; Faucette L; Eng WK; Johnson RK; Livi GP
Mol Cell Biol; 1993 Oct; 13(10):6012-23. PubMed ID: 8413204
[TBL] [Abstract][Full Text] [Related]
12. FAP48, a new protein that forms specific complexes with both immunophilins FKBP59 and FKBP12. Prevention by the immunosuppressant drugs FK506 and rapamycin.
Chambraud B; Radanyi C; Camonis JH; Shazand K; Rajkowski K; Baulieu EE
J Biol Chem; 1996 Dec; 271(51):32923-9. PubMed ID: 8955134
[TBL] [Abstract][Full Text] [Related]
13. Structure-activity studies of rapamycin analogs: evidence that the C-7 methoxy group is part of the effector domain and positioned at the FKBP12-FRAP interface.
Luengo JI; Yamashita DS; Dunnington D; Beck AK; Rozamus LW; Yen HK; Bossard MJ; Levy MA; Hand A; Newman-Tarr T
Chem Biol; 1995 Jul; 2(7):471-81. PubMed ID: 9383449
[TBL] [Abstract][Full Text] [Related]
14. Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP.
Choi J; Chen J; Schreiber SL; Clardy J
Science; 1996 Jul; 273(5272):239-42. PubMed ID: 8662507
[TBL] [Abstract][Full Text] [Related]
15. TOR kinase domains are required for two distinct functions, only one of which is inhibited by rapamycin.
Zheng XF; Florentino D; Chen J; Crabtree GR; Schreiber SL
Cell; 1995 Jul; 82(1):121-30. PubMed ID: 7606777
[TBL] [Abstract][Full Text] [Related]
16. The FKBP12-rapamycin-binding domain is required for FKBP12-rapamycin-associated protein kinase activity and G1 progression.
Vilella-Bach M; Nuzzi P; Fang Y; Chen J
J Biol Chem; 1999 Feb; 274(7):4266-72. PubMed ID: 9933627
[TBL] [Abstract][Full Text] [Related]
17. Molecular mechanisms of immunosuppression by cyclosporine, FK506, and rapamycin.
Cardenas ME; Zhu D; Heitman J
Curr Opin Nephrol Hypertens; 1995 Nov; 4(6):472-7. PubMed ID: 8591053
[TBL] [Abstract][Full Text] [Related]
18. Protein kinase activity and identification of a toxic effector domain of the target of rapamycin TOR proteins in yeast.
Alarcon CM; Heitman J; Cardenas ME
Mol Biol Cell; 1999 Aug; 10(8):2531-46. PubMed ID: 10436010
[TBL] [Abstract][Full Text] [Related]
19. Mammalian RAFT1 kinase domain provides rapamycin-sensitive TOR function in yeast.
Alarcon CM; Cardenas ME; Heitman J
Genes Dev; 1996 Feb; 10(3):279-88. PubMed ID: 8595879
[TBL] [Abstract][Full Text] [Related]
20. FK506 binding protein 12 mediates sensitivity to both FK506 and rapamycin in murine mast cells.
Fruman DA; Wood MA; Gjertson CK; Katz HR; Burakoff SJ; Bierer BE
Eur J Immunol; 1995 Feb; 25(2):563-71. PubMed ID: 7533090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
